Exercise activates a comprehensive suite of neuroprotective mechanisms against Parkinson's disease, including upregulation of neurotrophic factors BDNF, GDNF, VEGF and irisin, enhanced mitochondrial biogenesis, reduced neuroinflammation, and improved synaptic plasticity in the basal ganglia. Both preclinical models and clinical studies demonstrate preservation of dopaminergic neurons and improvements in motor function, balance, and quality of life. The research reveals exercise engages emerging protective pathways including vascular remodeling, cellular oxygen regulation, gut microbiome modulation, and epigenetic reprogramming. This represents a paradigm shift in understanding exercise not merely as symptomatic relief but as genuine disease modification. The convergence of animal and human data is particularly compelling, showing measurable improvements in exercise-responsive biomarkers like BDNF, irisin, and glutathione levels. For the millions facing Parkinson's risk or early-stage disease, this evidence positions structured physical activity as perhaps the most accessible and side-effect-free intervention available. The multifaceted nature of exercise's benefits—from cellular energy production to inflammation control—suggests it may be uniquely positioned to address Parkinson's complex pathophysiology where pharmaceutical approaches often target single pathways.